skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.08d (Release date: 2017-08-28)
SearchBox Top
SearchBox Bottom
Carboplatin-Taxol-Bevacizumab Regimen (Code C63413)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Carboplatin-Taxol-Bevacizumab Regimen

Definition: A chemoimmunotherapy regimen consisting of carboplatin, paclitaxel and bevacizumab used to treat advanced stage, non-small cell lung cancer which is not of the squamous cell histology.

NCI-GLOSS Definition: A chemotherapy combination used to treat advanced, nonsquamous non-small cell lung cancer. It includes the drugs carboplatin, paclitaxel (Taxol), and bevacizumab.

Label: Carboplatin-Taxol-Bevacizumab Regimen

NCI Thesaurus Code: C63413 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C1880001  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
Carbo-Taxol-Avastin Regimen
carboplatin-paclitaxel-bevacizumab regimen
carboplatin-Taxol-bevacizumab regimen
Carboplatin-Taxol-Bevacizumab Regimen

External Source Codes: 
PDQ Closed Trial Search ID 657275
PDQ Open Trial Search ID 657275 (check for NCI PDQ open clinical trial info)
UMLS CUI C1880001

Other Properties:
     Name Value (qualifiers indented underneath)
code C63413
DesignNote Source: NCCN Guidelines 2007
Legacy_Concept_Name Carboplatin-Taxol-Bevacizumab_Regimen
Semantic_Type Therapeutic or Preventive Procedure

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom